With longer follow-up out to one year, bleeding episodes have been almost completely eliminated for a small group of hemophilia B patients infused once with an experimental gene therapy from Spark Therapeutics (ONCE).

The updated results from Spark’s Phase 1/2 clinical trial, published Wednesday night in the New England Journal of Medicine, provide further evidence to support a groundbreaking change in the way the inherited blood-clotting disorder is treated — and potentially cured.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy